Sirtratumab vedotin

Sirtratumab vedotin (ASG15-ME) is an ADC composed of a SLITRK6-specific human gamma 2 antibody (Igγ2) conjugated to a small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE) via a protease-cleavable linker[1].

Product Specifications

CAS Number

[1824663-83-3]

Product Name Alternative

AGS15E; ASG-15ME; 1vcMMAE

UNSPSC

12352203

Target

Antibody-Drug Conjugates (ADCs)

Related Pathways

Antibody-drug Conjugate/ADC Related

Applications

Cancer-programmed cell death

Field of Research

Cancer

Purity

96.42

Solubility

H2O

Smiles

[Sirtratumabvedotin]

References & Citations

[1]Morrison K, et al. Development of ASG-15ME, a Novel Antibody-Drug Conjugate Targeting SLITRK6, a New Urothelial Cancer Biomarker. Mol Cancer Ther. 2016 Jun;15 (6) :1301-10.